Kazia Therapeutics Limited announced that it has entered into purchase agreement with new investor, Alumni Capital LP to issue fully paid ordinary shares, no par value for the aggregate gross proceeds of $15,000,000 on April 19, 2024. The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. Pursuant to the Purchase Agreement, the Company also agreed to file a registration statement with the Securities and Exchange Commission, covering the resale of the ADSs issued or sold to Alumni Capital under the Purchase Agreement under the Securities Act of 1933, as amended.